Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
收藏NIAID Data Ecosystem2026-03-10 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2266020
下载链接
链接失效反馈官方服务：
资源简介：
The POLE mutations represent high somatic mutation loads in patients with colorectal cancer, especially in those with MMR proficient or MSS, therefore, tumors harbouring POLE mutations might be susceptible to immune checkpoint blockade.
Based on these reasons, the investigators planned a phase II study of durvalumab monotherapy in patients with previously treated, metastatic, MMR deficient (MSI-H) or POLE mutated colorectal cancer.
创建时间：
2018-04-15
